scispace - formally typeset
K

Kirsty J. McLean

Researcher at University of Manchester

Publications -  123
Citations -  5244

Kirsty J. McLean is an academic researcher from University of Manchester. The author has contributed to research in topics: Mycobacterium tuberculosis & Gamma-ray burst. The author has an hindex of 37, co-authored 120 publications receiving 4736 citations. Previous affiliations of Kirsty J. McLean include Los Alamos National Laboratory & Elettra Sincrotrone Trieste.

Papers
More filters
Journal ArticleDOI

P450 BM3: the very model of a modern flavocytochrome.

TL;DR: The fundamental properties of P 450 BM3 are discussed and how progress with this model P450 has affected the authors' comprehension of P450 systems in general is discussed.
Journal ArticleDOI

Variations on a (t)heme--novel mechanisms, redox partners and catalytic functions in the cytochrome P450 superfamily.

TL;DR: The catalytic potential of the P450s in organic biotransformations is the subject of this review—with emphasis on the breadth of P450 redox systems now recognised and the catalytic versatility of these biotechnologically important enzymes.
Journal ArticleDOI

A link between prompt optical and prompt γ-ray emission in γ-ray bursts

TL;DR: In this paper, the authors reported a new optical component to internal shocks driven into the burst ejecta by variations of the inner engine, which is correlated with the prompt γ-rays, indicating a common origin for the optical light and the γrays.
Journal ArticleDOI

Cytochrome P450--redox partner fusion enzymes.

TL;DR: The current state of knowledge of the diversity of these P450-redox partner fusion proteins is examined and their structural composition and evolutionary origins are explored.
Journal ArticleDOI

Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes

TL;DR: When present at low concentrations in growth medium, azole antifungal drugs were shown to be potent inhibitors of the growth of Mycobacterium smegmatis and of Streptomyces strains, indicating that one or more of the P450s in these bacteria were viable drug targets.